Abstract P259: Cardiovascular Pharmacotherapy And Covid-19

• DOI: 10.1161/hyp.78.suppl_1.p259
• Publication Date: 2021-08-27T16:36:54Z
• Authors: Stefanie Lip; Linsay McCallum; Clea du Toit; Jason Kilmartin; Eleanor Murray; Salil Reetoo; Laura Knox; Maggie Rostron; Tomasz J Guzik; Christian Delles; Anna F Dominiczak; Rhian M Touyz; Sandosh Padmanabhan
• Keywords: Pharmacotherapy

COVID-19 illness is associated with cardiovascular vulnerabilities at all stages pre-infection, acute phase and subsequent chronic phase. The major cardiometabolic drivers identified to have epidemiological mechanistic associations are abnormal adiposity, dysglycaemia, dyslipidaemia, hypertension. Recent findings demonstrate that risk reduction interventions may short-term benefits on outcomes. Our aim was investigate the effect of pharmacotherapy SARS-CoV-2 infection. Demographic data, disease other comorbidities, prescription discharge outcomes, RT-PCR tests, investigations were obtained through record linkage for patients admitted between 01/04/2020 31/05/2020 NHS Greater Glasgow & Clyde hospitals. relationship (antihypertensives statins) infection analysed using multivariable logistic regression models. From 218,472 patient records available in SafeHaven. 3,610 had confirmed based clinical criteria or a positive test) 18,050 propensity matched controls selected. average age 62 years, 55% (1,985 3,610) females, 43% (1,552 resided most deprived areas (SIMD:1). There 46% (1,660 antihypertensive therapy 35% (1,264 statin therapy. greater those cancer, pulmonary renal model. Those an 11% (O.R.[95% CI]: 0.89 [0.82-0.97], p=0.007) 9% (0.91 [0.83-0.99], p=0.03) lower infection, respectively. protective statins drugs apparent only both drug therapies (0.82 [0.74-0.92], p=0.001). Prior treatment observed beneficial antihypertensives warrants further investigation address critical gaps knowledge prevention, long term follow up COVID-19.